drugset / Trial / NCT00566761

Treatment of Bevacizumab and Triamcinolone in Treatment or Macular Edema Secondary to CRVO

NCT00566761

Phase 4 Terminated 10 enrolled Asociación para Evitar la Ceguera en México
RandomizedParallel-groupOpen-labelTreatment

Summary

Treatment of macular edema secondary to central retinal vein occlusion is more effective with combined therapy of bevacizumab and triamcinolone than bevacizumab alone.

Timeline

Start
2007-06
Primary completion
2007-06
Completion
2008-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody 2.5 mg Intravitreal
Subject Triamcinolone Other / unclassified 4 mg Intravitreal